Home/Biosimilar Atlas/Companies/Bioviz Technologies

Bioviz Technologies

Biosimilar developer, India. 1 development product across 1 molecule: epoetin alfa and zeta.

First approval in the Atlas: Aug 2011, Bioviz Technologies (INN only), epoetin alfa and zeta (CDSCO)
FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved1
EDEproducts registered0
Connections
1molecule1product1 of 7markets0candidates in trials5companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
Epoetin alfa and zetaBioviz epoetin·····Aug 2011·1/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Bioviz Technologies, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

JCR PharmaceuticalsOne shared molecule: epoetin alfa and zeta3 molecules in its portfolioNorbitecOne shared molecule: epoetin alfa and zeta1 molecule in its portfolioSandozOne shared molecule: epoetin alfa and zeta10 molecules in its portfolioWockhardtOne shared molecule: epoetin alfa and zeta3 molecules in its portfolioZydus LifesciencesOne shared molecule: epoetin alfa and zeta11 molecules in its portfolio

Chronology

Compare Bioviz Technologies with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.